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Abstract
Background: Because excessive reduction in activities after back injury may impair recovery, it is important to
understand and address the factors contributing to the variability in motor responses to pain. The current dominant
theory is the "fear-avoidance model", in which the some patients' heightened fears of further injury cause them to avoid
movement. We propose that in addition to psychological factors, neurochemical variants in the circuits controlling
movement and their modification by pain may contribute to this variability. A systematic search of the motor research
literature and genetic databases yielded a prioritized list of polymorphic motor control candidate genes. We demonstrate
an analytic method that we applied to 14 of these genes in 290 patients with acute sciatica, whose reduction in movement
was estimated by items from the Roland-Morris Disability Questionnaire.
Results: We genotyped a total of 121 single nucleotide polymorphisms (SNPs) in 14 of these genes, which code for the
dopamine D2 receptor, GTP cyclohydrolase I, glycine receptor α1 subunit, GABA-A receptor α2 subunit, GABA-A
receptor β1 subunit, α-adrenergic 1C, 2A, and 2C receptors, serotonin 1A and 2A receptors, cannabinoid CB-1
receptor, M1 muscarinic receptor, and the tyrosine hydroxylase, and tachykinin precursor-1 molecules. No SNP showed
a significant association with the movement score after a Bonferroni correction for the 14 genes tested. Haplotype
analysis of one of the blocks in the GABA-A receptor β1 subunit showed that a haplotype of 11% frequency was
associated with less limitation of movement at a nominal significance level value (p = 0.0025) almost strong enough to
correct for testing 22 haplotype blocks.
Conclusion: If confirmed, the current results may suggest that a common haplotype in the GABA-A β1 subunit acts like
an "endogenous muscle relaxant" in an individual with subacute sciatica. Similar methods might be applied a larger set of
genes in animal models and human laboratory and clinical studies to understand the causes and prevention of pain-related
reduction in movement.
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Background
Pain-evoked limitation of activities is one of the most
costly morbidities of illness [1]. Several studies have rep-
licated the finding that bed rest or a decrease in activity
may impair recovery from an acute back pain episode [2-
5]. Clinical practice guidelines recommend early activity
in the management of acute low back pain [6,7].
If decreased activity in the presence of back pain retards
recovery, it may be important to understand why some
patients decrease their activity more than others after a
similar injury. Most of the relevant work to date has
focused on psychological causes of reductions in motor
activity in pain patients [8,9] paying relatively little atten-
tion to factors intrinsic to the motor system or direct con-
nections with afferent pain systems. For example, Lethem
et al [8] proposed the fear-avoidance model to explain a
possible mechanism of inactivity and disability in
patients with chronic musculoskeletal pain. According to
this hypothesis, if an individual misinterprets back pain as
a signal of reinjury or continued tissue damage, his fear of
injury may cause him to systematically avoid movements
that typically increase pain [10]. The resulting inactivity
may lead to deconditioning, contractures, and disability.
Psychological variables almost certainly explain some of
the variation in the motor response to injury, but we pro-
pose that one should also examine the contribution of
inter-individual differences in the wiring and neurochem-
istry of the motor system itself. Lund et al. [11] have pro-
posed a plausible link from pain inputs to motor circuits,
the "pain-adaptation model." In this model, pain afferent
activity decreases activity of the muscle groups that move
a joint in the pain-provoking direction and increases the
activity of muscle groups that antagonize such movement.
These motor adjustments reduce movement velocity and
limit excursions, thereby protecting against pain.
One way to examine potential differences in motor con-
trol processes is to test for polymorphisms in genes encod-
ing molecules that regulate motor systems. We and others
have already been studying the association between short
lists of candidate genetic polymorphisms and the severity
of acute and chronic pain [12-14] and pain-related mood
change [15]. Arrays of 500,000 or more single nucleotide
polymorphisms are commercially available, making pos-
sible whole genome association studies in large cohorts of
pain patients. It occurred to us that in cohorts where one
had a good measure of motor function, one could use the
same whole genome scan data to search for genes that pre-
disposed to a greater decrease in activity, given similar
injury and pain level. Many current spine pain studies will
include enough data to make this possible, because a dec-
ade ago, leading spine researchers [16] agreed that studies
should routinely incorporate either the Roland-Morris
[17] or Oswestry Disability questionnaires [18], which
question the patient about many motor functions.
We propose that there may be genetic polymorphisms
that directly affect the motor system to cause a maladap-
tive level of guarding and hypoactivity. In preparation for
our studies to test this hypothesis, we have examined the
literature on motor systems to suggest some candidate
genes. We previously proposed a method for prioritizing
genetic polymorphisms for clinical studies in which pain
intensity is the primary endpoint [19]. We have adapted
this into a method to prioritize polymorphisms that may
contribute to reduction in movement in the presence of
pain, and will describe this method and our resulting list
of plausible candidate genes.
Results
High priority motor control candidate genes
The prioritization process generated the candidate gene
list shown in Table 1, plus additional genes, not shown,
that scored lower than those in Table 1. Our literature
search showed that there was virtually no work specifi-
cally on the neurochemistry of pain-related motor
changes in mammalian models. Therefore, the ratings for
"relation to motor control" just reflect the degree of cer-
tainty that the molecule is present at key sites in motor
control systems, from basal ganglia down to the neu-
romuscular junction.
Non-genetic factors contributing to movement reduction
Table 2 shows the Roland-Morris Disability Question-
naire items that we included in the motor limitation sub-
scale. Figure 1 shows that patients with higher SF-36
bodily pain magnitude ratings reported greater movement
limitation. Pain rating contributed 31% of the variance in
movement impairment in patients who chose nonopera-
tive treatment, and 16% of the variance in those who
chose surgery. Table 3 shows other non-genetic contribu-
tors to variation in movement impairment. For this and
subsequent statistical analyses, we did not include pain
after observing that a two-factor, gene × pain analysis of
covariance for movement impairment yielded many more
significant genetic associations than would have occurred
by chance, even for lists of genes that were not on our
motor candidate list. Our only explanation for this was
that because the Roland-Morris movement questions
include wording referring to both pain and movement,
this might produce unanticipated biases of analyses that
include both pain and movement. Therefore we simpli-
fied the analysis by recognizing that all patients presented
to the study with leg and back pain – an entry criterion –
and dropping pain magnitude from the analysis. This step
corrected the number of SNP associations to the number
expected by chance.Molecular Pain 2007, 3:20 http://www.molecularpain.com/content/3/1/20
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Table 3 shows that greater reduction in movement was
associated with lower scores for the SF-36 Vitality subscale
(R2 = 29%); the choice of surgical treatment (R2 = 16%);
the patient receiving workers' compensation (R2 = 1.5%),
the presence of neurological deficits on exam (R2 = 4%),
and lower scores, indicating greater impairment, on the
SF-36 Emotional Role subscale (R2 = 12%). A combina-
tion of all of the variables in the model explained 44% of
the variance in the movement reduction subscale.
Analysis of 14 movement candidate genes and movement 
reduction
Resources permitted us to genotype a set of SNPs from 14
of these genes: 9 of the top priority 15 genes in Table 1,
and 5 lower priority genes that were included in the Lab-
oratory of Neurogenetics' array of 130 polymorphic genes
of interest to a consensus of neuropsychiatric and addic-
tions researchers. No SNPs in the fourteen genes we tested
– the dopamine D2 receptor, GTP cyclohydrolase I, gly-
cine receptor α1 subunit, GABA-A receptor α2 subunit,
GABA-A receptor β1 subunit, α-adrenergic 1C, 2A, and 2C
receptors, serotonin 1A and 2A receptors, cannabinoid
CB-1 receptor, M1 muscarinic receptor, and the tyrosine
hydroxylase, and tachykinin precursor-1 molecules –
showed a significant association with the movement score
after a Bonferroni correction for the multiple candidate
genes tested (Additional file 1). The two SNPs in the α-2C
adrenergic receptor that were nominally significant in the
additive model (without correction for multiple tests,
Table 4) made small contributions to the variance in
movement scores – approximately 0.6% and 0.9% (par-
tial R2). Neither of these SNPs is known to cause a func-
Table 1: High-priority candidate polymorphisms that may affect motor control.
Gene* Molecule SNP Location AA change Ref Frequency Function Relation to 
Motor 
Control
Total
%N o
DRD2/
ANKK1
Ankyrin 
repeat and 
kinase 
domain 1
C32806T 3' region/
Exon 8
G l u 7 1 3  L y s [ 4 2 ] 4 6 3339
GCH1 GTP 
cyclohydrola
se 1
C 9 4 A E x o n  1 T h r  9 4  L y s [ 1 4 ] 1 5 2338
GLRA1 Glycine 
receptor 1α
G 1 1 9 2 A E x o n  6 A r g 2 7 1  G l u [ 4 3 ] 1 2 2338
CACNA1S Calcium 
channel, 
voltage-
dependent, L 
type, α-1S 
subunit
T2403C Exon 18 no [44] 25 3238
GABR1A GABA A 
receptor 1 α
T 1 5 6 C E x o n  4 L y s 2 7 8  M e t [ 4 5 ] 2 8 2338
RyR1 Ryanodine 
receptor 1 
gene
G6178T Exon 38 Gly2060 Val [46] 12 2338
ADRA2C Adrenergic 
receptor 2C
12 NT Ins/
Del
Coding 
region/3rd 
intracellular 
loop
n o [ 4 7 ] 3 5 3227
5HT2A Serotonin 
2A receptor
T102C Exon 3 His 452 Tyr [48] 91337
GABBR1 GABAB 
receptor 
gene 1
G 1 4 6 5 A E x o n  1 1 G l y 4 8 9  S e r [ 4 9 ] 1 0 2226
ADRA2A α2A 
adrenergic 
receptor
C1291G Promoter 
region
n o [ 5 0 ] 2 6 2226
5HT1A Serotonin 
1A receptor
C1019G Promoter 
region
n o [ 5 1 ] 2 9 2226
CNR1 Cannabinoid 
receptor 
gene 1
G 1 3 5 9 A E x o n 1 n o [ 5 2 ] 3 1 3025
CHRM1 Human M1 
muscarinic 
receptor
C 1 2 2 1 T E x o n  6 C 4 0 7 [ 5 3 ] 1 6 2125
Rab3A Rat brain 
associated 
protein 3A
C 4 2 8 T E x o n 3 V a l 7 2  M e t [ 5 4 ] 2 6 2125
SCN4a Sodium 
channel 
receptor 
gene
A669G Exon 12 Arg672 Cys [55] NA 0235
*Genes listed in bold type were genotyped in this study, along with 5 intermediate-priority polymorphismsMolecular Pain 2007, 3:20 http://www.molecularpain.com/content/3/1/20
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tional change in molecular function. Haplotype analysis
of this gene using all four ADRA2C SNPs genotyped in
this study showed a nominally significant association (p =
0.02) with movement scores which loses significance
when one corrects for the 22 haplotype blocks examined.
Haplotype analysis of one of the blocks in the GABA-A
receptor β1 subunit showed that a haplotype of 11% fre-
quency was associated with less limitation of movement
at a significance level (p = 0.0025; Table 5) almost strong
enough to correct for testing 22 haplotype blocks.
Power analysis indicated that our study had sufficient
power (85%) to detect effect of a single SNP that contrib-
uted 5% (partial R2 = 0.05) of the movement variance
after correcting for Bonferonni error using α = 0.00357
(=0.05 divided by the number of genes tested, 14).
Discussion
Our literature review showed that the genes for many mol-
ecules associated with motor control circuits have com-
mon polymorphisms. Such polymorphisms might
conceivably contribute to excessive guarding shown by
some patients with pain.
The present study of 14 of these candidate genes revealed
an association of a GABA-A β1 subunit haplotype with the
amount of motor limitation (Table 5). Two copies of the
haplotype reduced movement limitation scores almost
30% compared with no copies. The nominal p value of
0.0025 is small enough to be interesting even if one cor-
rects for the 22 haplotype blocks examined, yielding an
overall p value = 0.055. If confirmed by subsequent stud-
ies, we would hypothesize that this variant of the gene
serves as an "endogenous muscle relaxant", with greater
GABAergic motor inhibitory activity that reduces spasm
and permits more activities.
We cannot speculate about the specific biochemical
mechanism by which this haplotype might affect motor
function. The finding that the haplotype analysis was
much more sensitive than single SNP analyses suggests
that a movement-facilitating SNP that we did not directly
test may be present on the haplotype we identified. Com-
pared to other GABA receptors, the GABA-A receptor β1
subunit has been little studied [20], and there is no com-
monly used specific antagonist, agonist, or knockout
mouse. The published literature states that benzodi-
azepine muscle relaxant effects are primarily mediated
through GABA-A α2, α3, and α5 receptor subunits [21].
However, interest in the β1 subunit is growing because of
possible associations with autism [22] and bipolar disor-
der [23], so the gene may soon be better understood.
The nominally significant associations of two ADRA2C
SNPs and a haplotype with motor limitation scores are
not persuasive because of the modest size of the effect and
the many genes tested. However, this gene is known to
Table 2: Roland-Morris Disability Questionnaire.
1 I stay at home most of the time because of my back problem or leg pain (sciatica).
2 I change position frequently to try and get my back or leg comfortable.
3 I walk more slowly than usual of my back problem or leg pain (sciatica).
4 Because of my back problem, I am not doing any of the jobs that I usually do around the house.
5 Because of back problem, I use a handrail to get to upstairs.
6 Because of my back problem, I have to hold onto something to get out of an easy chair.
7 I get dressed more slowly than usual because of my back problem or leg pain (sciatica).
8 I only stand for short periods of time because of my back problem or leg pain (sciatica).
9 Because of my back problem, I try not to bend or kneel down.
10 I find it difficult to get out of chair because of my back problem or leg pain (sciatica).
11 My back or leg is painful almost all the time.
12 I find it difficult to turn over the bed because of pain in my back or leg.
13 I have trouble putting on my socks (or stockings) because of the pain in my back or leg.
14 I only walk short distances because of my back or leg pain (sciatica).
15 I sleep less well because of my back problem.
16 I avoid heavy jobs around the house because of my back problem.
17 Because of my back problem, I am more irritable and bad tempered with people than usual.
18 Because of my back problem, I go upstairs more slowly than usual.
19 I stay in bed most of the time because of my back or leg pain (sciatica).
20 Because of my back problem, my sexual activity is decreased.
21 I keep rubbing or holding areas of my body that hurt or are uncomfortable.
22 Because of my back problem, I am doing less of the daily work around the house than I would usually do.
23 I often express concern to other people over what might be happening to my health.
Note: In the Maine Lumbar Spine Study, patients were asked to answer yes or no to each question to describe their condition "today," at study 
entry after referral to a specialist for acute or subacute sciatica. The total score is the number of items answered "yes." We selected the items in 
bold type as a "movement impairment" subscale.Molecular Pain 2007, 3:20 http://www.molecularpain.com/content/3/1/20
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have common polymorphisms with strong effects on car-
diovascular regulation and mood, such as a deletion
affecting about 40% of chromosomes in African Ameri-
cans [24,25], not tested for in the current study of a Cau-
casian population. Alpha-2 adrenergic receptors mediate
inhibition of motor tone at the spinal level [26], so this
gene should be revisited in future studies.
Because of several limitations in our study methods, we
consider these findings tentative. The first limitation is
that the Roland-Morris scale items that we used are retro-
spective and subjective assessments of the patient's ability
to carry out various movements of daily life. Moreover, we
chose a subset of these items to represent changes in
movement without any formal validation studies. Objec-
tive measures of motor function would have been more
convincing, but these were not available for this cohort.
Secondly, we tested only 14 genes, chosen by an anatom-
ical analysis the emphasized the final two or three neu-
rons in the motor control pathway. Molecules influencing
more rostral levels of control might also be candidates.
For example, Kleim et al. [27] have reported a BDNF pol-
ymorphism to be associated with modified plasticity in
the human motor cortex. A more thorough search could
be done using a whole genome association array, but this
would require a sample size in the thousands [23] to pro-
vide adequate power.
Thirdly, we would have been interested in searching for an
interaction between gene effect and pain level on move-
ment, similar to the gene, pain, and depression analysis
we have done on the same cohort [15]. For example, some
polymorphic alleles might produce a major reduction in
movement only in the presence of severe pain. However,
this analysis was not appropriate in this case because the
scale items mention both pain and various movements.
Finally, long-term decrease in movement is more directly
relevant to the economic burdens of pain than the acute
effects that we examined above. The analytical approach
demonstrated above might also be used to search for
effects of genes on a chronic decrease in movement. We
chose to examine acute pain and movement data as an ini-
tial demonstration of this method for several reasons: (1)
Almost all of our 290 patients who gave a DNA sample
had pain at the baseline measurement, while a minority
had persistent pain at one year or later time points. Sam-
ple size is crucial in screening multiple candidate genes
[19]. (2) A shorter time window in which patients are
Table 3: Variables that contribute to baseline Roland-Morris motor limitation subscale score.
Quantitative variable N Mean STD Correlation (r) with baseline Roland-
Morris
R2 p-value
SF-36 Vitality 309 40.00 21.74 -0.5384 0.2898 <0.0001
SF-36 Emotional 
Role
306 51.74 42.84 -0.3410 0.1163 <0.0001
Age 311 42.03 10.90 -0.0368 0.0014 0.5175
Baseline Roland-Morris
Categorical variable Category n Mean STD
Med vs. surgical 
treatment
Surgical 183 12.38 3.12 0.1605 <0.0001
Medical 128 9.02 4.60
Workman's 
compensation
Yes 114 11.67 3.77 0.0154 0.0288
No 197 10.60 4.29
Marital status Married/living 
together
244 11.00 4.18 0.0244 0.0223
Never Married 29 9.38 4.35
divorced/
separated/widow
38 12.18 3.30
Neurological exam 
deficits
0 76 9.74 4.51 0.0431 0.0037
each class 1 106 10.98 4.36
(motor, sensory, 
reflex)
2 97 11.64 3.50
counts for1 3 31 12.45 3.21
Sex Male 189 11.01 4.17 0.0000 0.9505
Female 122 10.98 4.09
R-square from the model including all above eight variables (n = 302 patients, model df = 9) 0.4420
Note: In the Maine Lumbar Spine Study, patients were asked to answer yes or no to each question to describe their condition "today," at study entry after referral to a 
specialist for acute or subacute sciatica. The total score is the number of items answered "yes." We selected the items in bold type as a "movement impairment" subscale.Molecular Pain 2007, 3:20 http://www.molecularpain.com/content/3/1/20
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studied under similar methods and treated by the same
clinicians may be more sensitive to genetic effects than a
longer period during which many types of environmental
variability overshadow gene effects. (3) The processes
involved in chronic pain and movement limitation are
probably more complex than acute pain, including decon-
ditioning, muscle atrophy and contractures, chronic psy-
chiatric morbidity, and occupational factors.
Although physicians commonly prescribe "muscle relax-
ants" such as cyclobenzaprine, carisoprodol, and meth-
ocarbamol for acute pain, the database supporting their
effects on muscle and clinical usefulness is limited [28].
Development of new treatments will require expansion of
animal research on the neurochemical mechanisms of
pain-related guarding. We propose that, as has been dem-
onstrated in genetic studies of pain [14], genomic screens
in humans may be useful in to prioritizing targets identi-
fied in animal studies.
Conclusion
We have illustrated a method to use routinely measured
variables in musculoskeletal pain studies to screen for
molecules that may be associated with the excessive pain-
related decrease in movement that increases risk of
chronic disability. After correction for multiple compari-
sons, we found a modestly significant association
between a haplotype in the GABA-β1 receptor subunit
with motor limitation scores. Replication of this finding
and the use of such methods with larger samples or direct
measures of movement [29,30] might open up a new facet
of the relationship between pain and movement.
Methods
Prioritization of "motor control" polymorphisms
Although muscle stiffness and reduction of movement in
pain patients is widely discussed in the literature [31,32],
there is no evidence regarding its molecular basis. Hence
we reviewed the motor control research from animal and
human studies to compile a list of molecules which
appear to be involved in normal motor control and in dis-
eases where muscle tone is altered and movement
restricted and muscle stiffness.
We searched the literature for reports of the transmitters,
receptors, and signaling molecules mediating control of
Impairment of movements involved in everyday activities on the day of study entry (Roland Morris Disability Questionnaire  subscale, Table 2) vs. magnitude of "bodily pain" (SF-36) in the month prior to study entry Figure 1
Impairment of movements involved in everyday activities on the day of study entry (Roland Morris Disability Questionnaire 
subscale, Table 2) vs. magnitude of "bodily pain" (SF-36) in the month prior to study entry. The patients are Maine Lumbar 
Spine Study sciatica cohort patients who subsequently chose nonsurgical (left) or surgical treatment (right). Some y axis values 
have been slightly altered to let the reader estimate the number of patients with overlapping data points. Not surprisingly, 
patients with more pain report limitation of more activities.
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limb and trunk movements, tone, and posture. We
searched PubMed for review articles on motor control
mechanisms and for citations of neurotransmitters, recep-
tors, or signaling molecules relevant to motor cortex,
brainstem, basal ganglia, cerebellum, locus coeruleus, cor-
ticospinal tract, ventral horn, interneuron, Renshaw cells,
and neuromuscular junction. We prioritized polymor-
phisms in the genes for these molecules similar to the cri-
teria proposed by Belfer et al. [19]. Three scores of 0–3
were assigned to each polymorphism according to (a) the
strength of evidence supporting involvement of the gene
in motor control; (b) population frequency of the poly-
morphism; and (c) strength of evidence that the polymor-
phism is associated with an altered clinical or molecular
phenotype.
A). Strength of evidence supporting the involvement of gene in motor 
control and muscle tone regulation
We assigned one point if a single paper reported anatom-
ical, physiological, or pharmacological evidence plausibly
associating the molecule with motor control, two points
for multiple reports, and three points for multiple reports
that show alterations of that molecule alter muscle tone in
animals or in patients.
B). Population frequency of polymorphism
Given equal effects on function, more common polymor-
phisms more efficient to study because there are sufficient
numbers of patients with one or two copies of the uncom-
mon allele. We assigned zero points if the population fre-
quency of the variant is less than 3%, one point for 4–9%,
two points for 10–29% and three points for 30–50%.
C). Functional effects of polymorphism
We made a PubMed and Panther database search and
assigned one point if the variant changed an amino acid,
two points for one report that the variant changes the
amount of mRNA or protein expression or function or is
associated with a clinical phenotype, and three points for
independent replication of any of these types of evidence.
Patients
Participants were members of the sciatica group in the
Maine Lumbar Spine Study (MLSS [33]). The MLSS was a
prospective cohort study conducted by approximately half
of Maine's orthopedists and neurosurgeons who actively
treated spine disease. Patients were enrolled between
1990 and 1992, and surgical discectomy or non-surgical
treatment was chosen based upon clinician judgment and
patient preference. Patients completed questionnaires at a
baseline assessment, and then at 3, 6, and 12 month fol-
low-up, and then annually through year 10. After comple-
tion of the 10 year study, the NIDCR and MLSS
investigators developed a collaboration to add a genetic
component to the study, under a protocol approved by
the NIDCR Institutional Review Board. Patients were
invited to contribute a DNA sample. Two hundred ninety
of the original 507 enrollees provided DNA and had usa-
ble baseline data.
Pain measure
The primary measure of pain for this study was the Bodily
Pain intensity item on the Short-Form-36 (SF-36) quality
of life instrument [34] at baseline. Patients responded to
the question "How much bodily pain have you had dur-
Table 4: Association of four ADRA2C markers with movement scores in sciatica patients
dbSNP ID Allele1 Allele2 Genotype Count Movement Score p Value*
rs13118771 T C 1/1 253 11.22 0.0267
1/2 53 10.16
2/2 4 9.87
rs6846820 A G1 / 1 6 9 . 1 9 0.0182
1/2 51 10.26
2/2 253 11.23
rs7434444 C G 1/1 16 11.63 0.4313
1/2 139 11.13
2/2 155 10.88
rs7678463 C G 1/1 6 9.35 0.2490
1/2 74 10.84
2/2 230 11.12
Haplotype analysis No. of haplotype 2121 (CAGC)
2 3 9.3 0.0216
1 52 10.2
0 255 11.2
p values shown are for additive model, which assumes that each copy of the uncommon allele alters the movement score by a similar amount, and uncorrected for examining 
121 SNPs in 22 haplotype blocks in 14 genes.Molecular Pain 2007, 3:20 http://www.molecularpain.com/content/3/1/20
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ing the past 4 weeks?" by choosing from "very severe,"
"severe," "moderate," "mild," "very mild," and "none."
Selection of "movement impairment subscale" from 
Roland-Morris
Table 2 lists the 23 items in The Roland-Morris Disability
Questionnaire. We selected the 16 items that refer to a
pain-related reduction in movement to comprise a
"movement impairment subscale." Each "yes" answer
contributes one point to the score.
Genotyping methods
DNA samples
Genomic DNA was extracted from lymphoblastoid cell
lines using a salting out protocol [35]. Additional DNA
samples were obtained from saliva samples collected
using Oragene self-collection kits and the DNA extracted
according to the manufacturer's recommendation.
Selection of genetic markers
One hundred twenty-one SNPs in the 14 genes studied
were selected based on the haplotypes reconstructed by
Haploview [36] or SNPHAP [37] with HapMap project
genotype data. A SNP selection pipeline based on a dou-
ble classification tree search algorithm [38] was used to
capture the haplotype complexities and the tag SNPs
(seleceted with Haploview for haplotype blocks).
Genotyping
We genotyped the DNAs using Illumina GoldenGate
chemistry on Sentrix Universal-96 Arrays. The Illumina
array used interrogates 1536 SNP simultaneously, using a
custom primer assay design (GS-0007064-OPA). 500 ng
of DNA per well was genotyped using standard Illumina
protocols. Arrays were imaged using an Illumina BeadSta-
tion 500 GX and data analyzed using GenCall 6.2.0.4 and
GTSreports v5.1.2.0 software (Illumina). Ten percent of
DNA samples were run in duplicate in order to obtain an
estimate of genotyping reproducibility. The overall error
rate was <0.005. Average genotyping completion rate was
>0.98. Hardy-Weinberg equilibrium for each marker was
tested with Chi-square tests using the R package "genetics"
[39] or exact tests [40]. No deviation from the expected
Hardy-Weinberg equilibrium values were observed for
any of the values analyzed.
Table 5: Association of six GABRB1 markers with movement scores in sciatica patients
dbSNP ID Allele1 Allele2 Genotype Count Movement 
Score
p Value*
rs4694846 A G 1/1 125 11.35 0.1862
1/2 136 10.85
2/2 49 10.81
rs17461905 A G 1/1 222 10.83 0.1219
1/2 84 11.46
2/2 4 11.73
rs13107066 A C 1/1 103 11.17 0.8874
1/2 136 10.84
2/2 71 11.09
rs6813436 A G 1/1 4 10.53 0.6383
1/2 68 11.29
2/2 238 10.96
rs7439087 A G 1/1 148 10.73 0.2294
1/2 131 11.29
2/2 31 11.19
rs 6290 T C 1/2 42 10.93 0.8447
2/2 268 11.04
Haplotype analysis No. of haplotype 211212 (GAAGAC)
28 8 . 5 0.0025
15 2 1 0 . 3
02 4 8 1 1 . 3
p values shown are for additive model, which assumes that each copy of the uncommon allele alters the movement score by a similar amount, and 
uncorrected for examining 121 SNPs in 22 haplotype blocks in 14 genes.Molecular Pain 2007, 3:20 http://www.molecularpain.com/content/3/1/20
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Inference of haplotypes
Haplotype phases – i.e., how the directly measured SNP
alleles were distributed into two chromosomes in each
patient – were inferred by the expectation – maximization
(EM) algorithm (SAS/Genetics, Cary, North Carolina,
USA).
Statistical analysis
Multiple linear regression was applied to examine the
association between movement and each SNP, adjusting
for eight other variables: age, sex, SF-36 Vitality, SF-36
Emotional Role, nonsurgical vs. surgical treatment, work-
man's compensation, marital status, and neurological
exam deficits. An additive genetic model was tested by
recoding the three SNP genotypes as 0 for the homozygote
of the common allele, 1 for the heterozygote, and 2 for
homozygote of the uncommon allele. In the haplotype
analysis, first haplotype phases were inferred using expec-
tation-maximization (EM) algorithm, where the probabil-
ity was assigned to each pair of haplotypes which each
subject possessed. Then, stepwise regression [41] was
applied to test the association between movement score
and haplotypes; the linear regression model included all
haplotypes with frequency greater than 1% and the eight
covariates.
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